Servicio de Neumología, Hospital Son Llàtzer, Palma de Mallorca, España.
Servicio de Dermatología, Hospital Universitario de la Princesa, Madrid, España.
Arch Bronconeumol. 2016 Jan;52(1):36-45. doi: 10.1016/j.arbres.2015.04.016. Epub 2015 Jul 14.
Tuberculosis risk is increased in patients with chronic inflammatory diseases receiving any immunosuppressive treatment, notably tumor necrosis factor (TNF) antagonists therapy. Screening for the presence of latent infection with Mycobacterium tuberculosis and targeted preventive treatment to reduce the risk of progression to TB is mandatory in these patients. This Consensus Document summarizes the current knowledge and expert opinion of biologic therapies including TNF-blocking treatments. It provides recommendations for the use of interferon-gamma release assays (IGRA) and tuberculin skin test (TST) for the diagnosis of latent tuberculosis infection in these patients, and for the type and duration of preventive therapy.
结核病风险在接受任何免疫抑制治疗的慢性炎症性疾病患者中增加，尤其是肿瘤坏死因子（TNF）拮抗剂治疗。在这些患者中，筛查潜伏性结核分枝杆菌感染的存在并进行有针对性的预防治疗以降低进展为结核病的风险是强制性的。本共识文件总结了生物治疗包括 TNF 阻断治疗的当前知识和专家意见。它为这些患者中潜伏性结核感染的诊断以及预防治疗的类型和持续时间提供了干扰素-γ释放试验（IGRA）和结核菌素皮肤试验（TST）的使用建议。
